Precision medicine! Roche launched the companion diagnostic kit Ventana PD-L1 to accurately identify PD-L1 positive and three negative breast cancer patients!

August 30, 2019 / BIOON / -- Roche, a Swiss pharmaceutical giant, recently announced the launch of Ventana PD-L1 (sp142) test kit in CE certification market, which is used to determine three negative breast cancer TNBC patients are eligible for the first concomitant diagnostic kit for the treatment of PD-L1 tumor immunotherapy tecentriq (atezolizumab) combined with chemotherapy (NAB paclitaxel, albumin binding paclitaxel) The kit can identify the patients who are most likely to benefit from the treatment by evaluating the status of PD-L1 biomarkers infiltrating immune cells This product launch is an important step in Roche's individualized medical strategy, aiming to provide appropriate treatment for patients who benefit most from specific drugs Globally, more than 300000 patients are diagnosed with TNBC every year, which is an invasive breast cancer with very limited treatment options Ventana PD-L1 (sp142) test kit is helpful to identify TNBC patients who are most likely to benefit from tecentriq combined chemotherapy In March this year, the accompanying diagnostic kit was approved by the US FDA, and is the first diagnostic standard used in the US market to determine whether TNBC patients meet the tecentriq + chemotherapy program The diagnosis of TNBC means that the three most common proteins related to breast cancer growth - estrogen receptor (ER), progesterone receptor (PR) and Her22 / neu - are not expressed in tumors The Ventana PD-L1 (sp142) test kit enhanced the visual contrast of tumor infiltrating immune cells In TNBC, PD-L1 is mainly expressed in tumor infiltrating immune cells rather than tumor cells themselves The Ventana PD-L1 (sp142) test kit can be used for specific staining of tumor cells and immune cells The product has previously been approved by FDA and CE, and can be used as an assistant diagnosis of urothelial carcinoma (UC) or as a predictive test of tecentriq in the treatment of non-small cell lung cancer (NSCLC) For more information on the level of PD-L1 expression in the guidelines for the treatment of various cancer indications, see the tecentriq product label Ventana PD-L1 (sp142) test kit was launched in 2016 It is the main diagnostic test kit of tecentriq clinical development project, which is used for patients in the group and stratified tecentriq clinical trials The kit was used in the group test of patients in impression130 clinical trial, which is the first active phase III immunotherapy protocol study in the field of triple negative breast cancer (TNBC) The kit is the first to use immunocytochemistry and tumor microenvironment scores to assess the status of PD-L1 biomarkers in patients Recently, based on the data of impression130 clinical research, tecentriq and chemotherapy (NAB paclitaxel, albumin binding paclitaxel) combination scheme has been approved by the European Union as an initial therapy for the treatment of unresectable locally advanced or metastatic triple negative mammary gland with PD-L1 (≥ 1%) expression in tumor and without previous chemotherapy (chemotherapy initial treatment) to control metastatic disease Cancer (TNBC) in adults In the United States, tecentriq + Abraxane combination has been approved by the FDA for use in unresectable locally advanced or metastatic TNBC patients with tumor expression of PD-L1 In the United States and the European Union, tecentriq + chemotherapy (albumin binding paclitaxel) combination is the first cancer immunotherapy scheme approved by regulatory authorities for the treatment of PD-L1 positive metastatic TNBC Source: Roche launches Ventana PD-L1 (sp142) assay in CE markets as first company diagnostic to identify triple negative breast cancer patients eligible for treatment with tecentriq